60 Degrees Pharmaceuticals Announces Tafenoquine Updates For Babesiosis
The company presented data at the 2026 ILADS conference indicating converging evidence across acute, relapsing, and chronic babesiosis settings. A potential supplemental New Drug Application (sNDA) in 2027 is also planned.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed